Immune Checkpoint Blockade Across the Cancer Care Continuum

Overview

Journal Immunity

Publisher Cell Press

Specialty Allergy & Immunology

Date 2018 Jun 21

PMID 29924973

Citations 16

Authors

Beth A Helmink

Pierre-Olivier Gaudreau

Jennifer A Wargo

Affiliations

Soon will be listed here.

Abstract

Four studies recently reported in the New England Journal of Medicine highlight advances in treatment with immune checkpoint blockade across the cancer care continuum. These findings demonstrate efficacy of these agents in the treatment of early and late-stage disease, as monotherapy or in combination, and in addition to-or in place of-standard front-line therapy.

Citing Articles

Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors.

Xiong W, Xiao L, Duan R, Wang Q, Xian M, Zhang C J Immunother Cancer. 2025; 13(1.

PMID: 39755583 PMC: 11749690. DOI: 10.1136/jitc-2024-008979.

Conventional type 1 dendritic cells (cDC1) in cancer immunity.

Liu P, Zhao L, Kroemer G, Kepp O Biol Direct. 2023; 18(1):71.

PMID: 37907944 PMC: 10619282. DOI: 10.1186/s13062-023-00430-5.

Recent advances in 2D material-based phototherapy.

Tan Y, Khan H, Sheikh B, Sun H, Zhang H, Chen J Front Bioeng Biotechnol. 2023; 11:1141631.

PMID: 36937746 PMC: 10020212. DOI: 10.3389/fbioe.2023.1141631.

Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.

Wu L, Xu Y, Wang X, Cheng X, Zhang Y, Wang Y Endocrine. 2023; 81(1):123-133.

PMID: 36867366 DOI: 10.1007/s12020-023-03323-9.

Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment.

Shen J, Gao H, Chen L, Jiang Y, Li S, Chao Y Sci Adv. 2023; 9(4):eabq3104.

PMID: 36706184 PMC: 9882978. DOI: 10.1126/sciadv.abq3104.